Strides Pharma Science Ltd approves Q2 FY27 results, with revenue of ₹1,429.7 crore up 17.1% year on year
- Consolidated EBIT margin was 13.8%; net profit was ₹134.1 crore, up 2.0% YoY and down 19.0% sequentially.
- Revenue increased 13.0% sequentially; results include a ₹1.7 crore exceptional expense related to product recalls and settlements.
- Auditor issued an unmodified limited-review conclusion; certain subsidiary results were not reviewed.